Skip to content

Advertisement

Open Access

Correction to: Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene

  • Duarte Mendes Oliveira1,
  • Katia Grillone1,
  • Chiara Mignogna2,
  • Valentina De Falco4,
  • Carmelo Laudanna1,
  • Flavia Biamonte1,
  • Rosa Locane3,
  • Francesco Corcione5,
  • Massimiliano Fabozzi5,
  • Rosario Sacco3,
  • Giuseppe Viglietto1Email author,
  • Donatella Malanga1Email author and
  • Antonia Rizzuto3
Journal of Experimental & Clinical Cancer Research201837:112

https://doi.org/10.1186/s13046-018-0776-5

Received: 18 April 2018

Accepted: 18 April 2018

Published: 1 June 2018

The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:84

Correction

In the publication of this article [1], there is an error in Fig. 7. The minus and plus signals are inverted which impairs understanding of the results described.

Figure 7 should instead be read as indicated in this correction.

Figure 1
Fig. 7

From: Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. The RET-G533C mutant is inhibited by vandetanib. a. MTT assay was performed in the presence of two different concentrations of vandetanib. HEK293 cells expressing pBabe were used as negative control and HEK293 cells expressing RET-C634R mutant were used as positive control. Values are shown as bar graphs and all results are the average of experiments performed in triplicate. Statistical significance compared with vehicle was evaluated by Two-Way ANOVA (with multiple comparison Dunnet’s test) (n = 3; **p < 0.01; ***p < 0.001). b. Immunoblot analysis of RET/MAPK pathway (with anti-phosphoY1062 RET, anti-RET, anti phospho-Y202T204 ERK1/2, anti-ERK1/2 antibodies) of HEK293 cells transfected with RET-G533C mutant treated with vehicle or vandetanib (500 nM) for 2 h. HEK293 cells transfected with RET-634 mutant were used as control

This has now been included in this erratum.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
(2)
Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
(3)
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
(4)
Department of Molecular Medicine and Medical Biotechnologies, University Federico II, Naples, Italy
(5)
UOC Chirurgia Generale, Azienda Ospedaliera dei Colli, Naples, Italy

Reference

  1. Mendes Oliveira D, Grillone K, Mignogna C, et al. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. J Exp Clin Cancer Res. 2018;37:84. https://doi.org/10.1186/s13046-018-0746-yView ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement